Floatz logo

Solu-Cortef

Endocrine Disease

Neurocrine UK LimitedPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Endocrine Disease cohort.

Asset / SponsorPhaseRating
Hcg
Merck KGaA, Darmstadt, Germany
Phase 3BB
TESTOSTERONE UNDECYLATE
Craig Hospital
Phase 4BB
Msj-0011
Merck KGaA, Darmstadt, Germany
Phase 3BB
Follitropin Alpha
Merck KGaA, Darmstadt, Germany
Phase 3BB
Irinotecan
Xiaoxiang Chen
Phase 2BB

View all 27 →

Same molecule, other indications

Solu-Cortef is also rated in:

congenital adrenal hyperplasiaDormant
A
Indicative ·
81 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →